EyePoint Pharmaceuticals Files 8-K
Ticker: EYPT · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financials, amendment
Related Tickers: EYPT
TL;DR
EYPT filed an 8-K on 12/8/25 for corporate changes & financials.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on December 8, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as pSivida Corp. and pSivida LTD, is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing indicates potential corporate structure changes or the release of financial information, which could impact investors' understanding of the company's operational status and governance.
Risk Assessment
Risk Level: low — This is a routine filing for corporate updates and financial reporting, not indicating immediate operational or financial distress.
Key Numbers
- 000-51122 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-2774444 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive offices
- December 8, 2025 (date) — Date of report
FAQ
What specific amendments were made to EyePoint Pharmaceuticals' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the excerpt.
What is the significance of filing financial statements and exhibits with this 8-K?
Filing financial statements and exhibits provides updated financial information and supporting documents to the SEC and the public, which could relate to the corporate changes mentioned.
When did EyePoint Pharmaceuticals change its name from pSivida Corp.?
The date of the name change from pSivida Corp. was June 19, 2008.
What is the primary business address of EyePoint Pharmaceuticals?
The primary business address is 480 Pleasant Street, Suite C400, Watertown, Massachusetts 02472.
What is the fiscal year end for EyePoint Pharmaceuticals?
The fiscal year end for EyePoint Pharmaceuticals is December 31.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-12-08 09:49:43
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Indi
Filing Documents
- d60563d8k.htm (8-K) — 26KB
- d60563dex31.htm (EX-3.1) — 7KB
- d60563dex32.htm (EX-3.2) — 4KB
- 0001193125-25-310731.txt ( ) — 152KB
- eypt-20251208.xsd (EX-101.SCH) — 3KB
- eypt-20251208_lab.xml (EX-101.LAB) — 18KB
- eypt-20251208_pre.xml (EX-101.PRE) — 11KB
- d60563d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Certificate of Incorporation. 3.2 Amendment No. 2 to the By-Laws. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EyePoint Pharmaceuticals, Inc. Date: December 8, 2025 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer